News | September 04, 2024
Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The emergence of new infections in India is a growing concern
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
The academy has secured partnerships with 15 esteemed hospitals
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
The Issue opened on June 18, 2024 and closed on June 21, 2024
Achira is engaged in development and commercialization of PoC medical test kits in India
Subscribe To Our Newsletter & Stay Updated
